Allogene Therapeutics
ALLO • NASDAQ
Allogene Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO David D. Chang, with a market cap of $550.9M.
Market Cap$550.9M
Employees361.0
CEODavid D. Chang
CountryUnited States of America
Healthcare
Biotechnology
Next EarningsMay 12, 2026 · in a monthQ1 2026
Financials
Allogene Therapeutics FAQ
Common questions about Allogene Therapeutics
Allogene Therapeutics is scheduled to report earnings for Q1 2026 on May 12, 2026. Analysts estimate revenue of $2.0K.
Allogene Therapeutics has approximately 361 employees.